|
1
|
Geller DS and Gorlick R: Osteosarcoma: A
review of diagnosis, management, and treatment strategies. Clin Adv
Hematol Oncol. 8:705–718. 2010.
|
|
2
|
Messerschmitt PJ, Rettew AN, Brookover RE,
Garcia RM, Getty PJ and Greenfield EM: Specific tyrosine kinase
inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop
Relat Res. 466:2168–2175. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Vega S, Iwamoto T and Yamada Y:
Fibulins: Multiple roles in matrix structures and tissue functions.
Cell Mol Life Sci. 66:1890–1902. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kobayashi N, Kostka G, Garbe JH, Keene DR,
Bächinger HP, Hanisch FG, Markova D, Tsuda T, Timpl R, Chu ML, et
al: A comparative analysis of the fibulin protein family.
Biochemical characterization, binding interactions, and tissue
localization. J Biol Chem. 282:11805–11816. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Papke CL and Yanagisawa H: Fibulin-4 and
fibulin-5 in elastogenesis and beyond: Insights from mouse and
human studies. Matrix Biol. 37:142–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Obaya AJ, Rua S, Moncada-Pazos A and Cal
S: The dual role of fibulins in tumorigenesis. Cancer Lett.
325:132–138. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moll F, Katsaros D, Lazennec G, Hellio N,
Roger P, Giacalone PL, Chalbos D, Maudelonde T, Rochefort H and
Pujol P: Estrogen induction and overexpression of fibulin-1C mRNA
in ovarian cancer cells. Oncogene. 21:1097–1107. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Greene LM, Twal WO, Duffy MJ, McDermott
EW, Hill AD, O'Higgins NJ, McCann AH, Dervan PA, Argraves WS and
Gallagher WM: Elevated expression and altered processing of
fibulin-1 protein in human breast cancer. Br J Cancer. 88:871–878.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kanda M, Nomoto S, Okamura Y, Hayashi M,
Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S and Nakao A:
Promoter hypermethylation of fibulin 1 gene is associated with
tumor progression in hepatocellular carcinoma. Mol Carcinog.
50:571–579. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cheng YY, Jin H, Liu X, Siu JM, Wong YP,
Ng EK, Yu J, Leung WK, Sung JJ and Chan FK: Fibulin 1 is
downregulated through promoter hypermethylation in gastric cancer.
Br J Cancer. 99:2083–2087. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wlazlinski A, Engers R, Hoffmann MJ, Hader
C, Jung V, Müller M and Schulz WA: Downregulation of several
fibulin genes in prostate cancer. Prostate. 67:1770–1780. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xie L, Palmsten K, MacDonald B, Kieran MW,
Potenta S, Vong S and Kalluri R: Basement membrane derived
fibulin-1 and fibulin-5 function as angiogenesis inhibitors and
suppress tumor growth. Exp Biol Med (Maywood). 233:155–162. 2008.
View Article : Google Scholar
|
|
13
|
Law EW, Cheung AK, Kashuba VI, Pavlova TV,
Zabarovsky ER, Lung HL, Cheng Y, Chua D, Lai-Wan Kwong D, Tsao SW,
et al: Anti-angiogenic and tumor-suppressive roles of candidate
tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma.
Oncogene. 31:728–738. 2012. View Article : Google Scholar
|
|
14
|
Yi CH, Smith DJ, West WW and Hollingsworth
MA: Loss of fibulin-2 expression is associated with breast cancer
progression. Am J Pathol. 170:1535–1545. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Seeliger H, Camaj P, Ischenko I, Kleespies
A, De Toni EN, Thieme SE, Blum H, Assmann G, Jauch KW and Bruns CJ:
EFEMP1 expression promotes in vivo tumor growth in human pancreatic
adenocarcinoma. Mol Cancer Res. 7:189–198. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Song EL, Hou YP, Yu SP, Chen SG, Huang JT,
Luo T, Kong LP, Xu J and Wang HQ: EFEMP1 expression promotes
angiogenesis and accelerates the growth of cervical cancer in vivo.
Gynecol Oncol. 121:174–180. 2011. View Article : Google Scholar
|
|
17
|
En-lin S, Sheng-Guo C and Hua-qiao W: The
expression of EFEMP1 in cervical carcinoma and its relationship
with prognosis. Gynecol Oncol. 117:417–422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu B, Thirtamara-Rajamani KK, Sim H and
Viapiano MS: Fibulin-3 is uniquely upregulated in malignant gliomas
and promotes tumor cell motility and invasion. Mol Cancer Res.
7:1756–1770. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hwang CF, Chien CY, Huang SC, Yin YF,
Huang CC, Fang FM, Tsai HT, Su LJ and Chen CH: Fibulin-3 is
associated with tumour progression and a poor prognosis in
nasopharyngeal carcinomas and inhibits cell migration and invasion
via suppressed AKT activity. J Pathol. 222:367–379. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sadr-Nabavi A, Ramser J, Volkmann J,
Naehrig J, Wiesmann F, Betz B, Hellebrand H, Engert S, Seitz S,
Kreutzfeld R, et al: Decreased expression of angiogenesis
antagonist EFEMP1 in sporadic breast cancer is caused by aberrant
promoter methylation and points to an impact of EFEMP1 as molecular
biomarker. Int J Cancer. 124:1727–1735. 2009. View Article : Google Scholar
|
|
21
|
Hu Y, Pioli PD, Siegel E, Zhang Q, Nelson
J, Chaturbedi A, Mathews MS, Ro DI, Alkafeef S, Hsu N, et al:
EFEMP1 suppresses malignant glioma growth and exerts its action
within the tumor extracellular compartment. Mol Cancer. 10:1232011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schluterman MK, Chapman SL, Korpanty G,
Ozumi K, Fukai T, Yanagisawa H and Brekken RA: Loss of fibulin-5
binding to beta1 integrins inhibits tumor growth by increasing the
level of ROS. Dis Model Mech. 3:333–342. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu Z, Ai Q, Xu H, Ma X, Li HZ, Shi TP,
Wang C, Gong DJ and Zhang X: Fibulin-5 is down-regulated in
urothelial carcinoma of bladder and inhibits growth and invasion of
human bladder cancer cell line 5637. Urol Oncol. 29:430–435. 2011.
View Article : Google Scholar
|
|
24
|
Yue W, Sun Q, Landreneau R, Wu C,
Siegfried JM, Yu J and Zhang L: Fibulin-5 suppresses lung cancer
invasion by inhibiting matrix metalloproteinase-7 expression.
Cancer Res. 69:6339–6346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Albig AR and Schiemann WP: Fibulin-5
function during tumorigenesis. Future Oncol. 1:23–35. 2005.
View Article : Google Scholar
|
|
26
|
Omasu F, Nakano Y and Ichiki T:
Measurement of the electrophoretic mobility of sheep erythrocytes
using microcapillary chips. Electrophoresis. 26:1163–1167. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen J, Zhang J, Zhao Y, Li J and Fu M:
Integrin beta3 down-regulates invasive features of ovarian cancer
cells in SKOV3 cell subclones. J Cancer Res Clin Oncol.
135:909–917. 2009. View Article : Google Scholar
|
|
28
|
Chang XZ, Wang ZM, Yu JM, Tian FG, Jin W,
Zhang Y, Yu J, Li LF, Liu XF, Li ZW, et al: Isolation of a human
gallbladder cancer cell clone with high invasive phenotype in vitro
and metastatic potential in orthotopic model and inhibition of its
invasiveness by heparanase antisense oligodeoxynucleotides. Clin
Exp Metastasis. 24:25–38. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen J, Liu Z, Fang S, Fang R, Liu X, Zhao
Y, Li X, Huang L and Zhang J: Fibulin-4 is associated with tumor
progression and a poor prognosis in ovarian carcinomas. BMC Cancer.
15:912015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang X, Li D, Cheng S, Fan K, Sheng L,
Zhang J, Feng B and Xu Z: The correlation of bone morphogenetic
protein 2 with poor prognosis in glioma patients. Tumour Biol.
35:11091–11095. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Albini A, Iwamoto Y, Kleinman HK, Martin
GR, Aaronson SA, Kozlowski JM and McEwan RN: A rapid in vitro assay
for quantitating the invasive potential of tumor cells. Cancer Res.
47:3239–3245. 1987.PubMed/NCBI
|
|
32
|
Li R and Wang L: Fibulin-4 is a novel
Wnt/β-catenin pathway activator in human osteosarcoma. Biochem
Biophys Res Commun. 474:730–735. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gallagher WM, Greene LM, Ryan MP, Sierra
V, Berger A, Laurent-Puig P and Conseiller E: Human fibulin-4:
Analysis of its biosynthetic processing and mRNA expression in
normal and tumour tissues. FEBS Lett. 489:59–66. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yao L, Lao W, Zhang Y, Tang X, Hu X, He C,
Hu X and Xu LX: Identification of EFEMP2 as a serum biomarker for
the early detection of colorectal cancer with lectin affinity
capture assisted secretome analysis of cultured fresh tissues. J
Proteome Res. 11:3281–3294. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen J, Zhang J, Liu X, Fang R, Zhao Y and
Ma D: Overexpression of fibulin-4 is associated with tumor
progression and poor prognosis in patients with cervical carcinoma.
Oncol Rep. 31:2601–2610. 2014.PubMed/NCBI
|
|
36
|
Wang L, Chen Q, Chen Z, Tian D, Xu H, Cai
Q, Liu B and Deng G: EFEMP2 is upregulated in gliomas and promotes
glioma cell proliferation and invasion. Int J Clin Exp Pathol.
8:10385–10393. 2015.PubMed/NCBI
|
|
37
|
Chen L, Sun B, Zhang S, Zhao X, He Y, Zhao
S, Lin T and Li X: Influence of microenvironments on
microcirculation patterns and tumor invasion-related protein
expression in melanoma. Oncol Rep. 21:917–923. 2009.PubMed/NCBI
|
|
38
|
Lau LF: CCN1/CYR61: The very model of a
modern matri-cellular protein. Cell Mol Life Sci. 68:3149–3163.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lau LF: Cell surface receptors for CCN
proteins. J Cell Commun Signal. 10:121–127. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hou CH, Lin FL, Hou SM and Liu JF: Cyr61
promotes epithelial-mesenchymal transition and tumor metastasis of
osteosarcoma by Raf-1/MEK/ERK/Elk-1/TWIST-1 signaling pathway. Mol
Cancer. 13:2362014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Habel N, Vilalta M, Bawa O, Opolon P,
Blanco J and Fromigué O: Cyr61 silencing reduces vascularization
and dissemination of osteosarcoma tumors. Oncogene. 34:3207–3213.
2015. View Article : Google Scholar
|
|
42
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li X, Wu C, Chen N, Gu H, Yen A, Cao L,
Wang E and Wang L: I3K/Akt/mTOR signaling pathway and targeted
therapy for glioblastoma. Oncotarget. 7:33440–33450.
2016.PubMed/NCBI
|
|
44
|
Gao Y, Yuan CY and Yuan W: Will targeting
PI3K/Akt/mTOR signaling work in hematopoietic malignancies? Stem
Cell Investig. 3:312016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang Y and Marmorstein LY: Focus on
molecules: Fibulin-3 (EFEMP1). Exp Eye Res. 90:374–375. 2010.
View Article : Google Scholar :
|
|
46
|
Kim IG, Kim SY, Choi SI, Lee JH, Kim KC
and Cho EW: Fibulin-3-mediated inhibition of
epithelial-to-mesenchymal transition and self-renewal of
ALDH+ lung cancer stem cells through IGF1R signaling.
Oncogene. 33:3908–3917. 2014. View Article : Google Scholar
|
|
47
|
Camaj P, Seeliger H, Ischenko I, Krebs S,
Blum H, De Toni EN, Faktorova D, Jauch KW and Bruns CJ: EFEMP1
binds the EGF receptor and activates MAPK and Akt pathways in
pancreatic carcinoma cells. Biol Chem. 390:1293–1302. 2009.
View Article : Google Scholar : PubMed/NCBI
|
